Thiopoietins: a new
generation of immunomodulators.
On the basis of original concepts developed by BAM
Ltd. (
A specific drugs' feature is their ability for
diferenziated impact on normal and transfomed (including virus infected) cells.
Infact, under the influence of thiopoietins, proliferation and differentiation
of the normal cells are stimulated as well as process of the genetically
programmed cell death (apoptosis) in the transformed cells are activated.
Having a unique capability of inducing p53-dependent and p53-independent
apoptosis pathways in the transformend cells only, the above said drugs
pricipally increase the cancer cells sensitivity to conventional anticancer
drugs. Through activation of the normal cell metabolism, proliferation and differentiation,
thiopoietins simultaneously increase the normal cell resistance against
chemotherapy impacts preventing hepato-, nephro-, cardio- and nurotoxicity.
Considering molecular mechanisms of action (modulation
of endogenous production of the wide cytokines range, reproduction of the p53,
p21 and ras-proteins' effects), the medical indication of thiopoietins is a new
level of immunological support for the antibacterial, antiviral and antitumor
chemo- and radiotherapy.
Thus the matter in hand is the novel methodology, even
the novel ideology of antitumor and antiviral chemotherapy, which provides
absolutely new treatment efficacy and patients'quality of life.
Two drugs are up to now approved for human use and
these are Glutoxim ® and Molixan ®.
Dr. Giorgio Castello
Via A. Cecchi, 19/9
16129 – Genova (Italy)
Tel:
Mobil
phone:
e-mail:
castello@tiopoietine.info
©
2005. All rights reserved. No part of this paper may be reproduced without the
written permission of the author.